40,000 sq ft development well underway at Granta Park

Construction started in June on PPD’s latest phase of development at Granta Park and 55 % of the steel frame is already complete. “Progress on the steel frame has been excellent. Approximately 55% has now been erected and the metal decking work has commenced.” Said Chris Travers Project Manager for Mace the construction managers on site working for Granta Park.

The 40,000 sq ft development completes the next stage in the growth of PPD’s campus-style facility at Granta Park. PPD moved to Granta Park in 2002 taking 28,500 sq ft in its first pre let. The first expansion, called “PPD Phase II,” was completed in 2005 and added 22,000 sq ft. The expansion will be completed by autumn 2009 and will include office areas and a training suite. Once complete, PPD will occupy 90,000 sq ft at the Cambridge facility.

“We are very pleased with the progress of the PPD building and with 330,000 sq ft of outline consent on Granta Park Phase II we are looking to attract other high-tech companies who would benefit from our good practice approach.” Commented John Granger, Granta Park Managing Director.

From above

See how Granta Park is progressing from above:

Granta joins the social network revolution

Granta Park has set up a facebook page. Hopefully this will develop over the coming months to provide a resource of information for what’s happening on the science park here in Cambridge

Click to view our page

Also live on BT's Trade Space

http://grantapark-scienceparkcambridge.bttradespace.com/

Offices and Laboratories To Let/Rent Cambridge

Granta Park Science Park Cambridge currently has a number of new office and laboratory developments underway that will provide office and laboratory space. For futher information click the link below:
Offices & Laboratory To Let/Rent Cambridge

Vernalis Announcement of Interim results

In the first half of 2008, Vernalis implemented a major change in its business strategy and is now focused on pursuing its R&D programmes up to and including proof of concept clinical studies whilst seeking partnerships for later-phase clinical development and commercialisation. Vernalis has completed a major restructuring to provide a stable financial platform for this R&D based strategy. Vernalis also today announces the successful completion of a Phase IIa study with V10153, a potential treatment for ischaemic stroke.

Peter Fellner, Executive Chairman, Vernalis commented, “In the first half of 2008, we have completed the restructuring of Vernalis, as planned and on schedule. The divestment of Apokyn® and the US operations together with utilisation of frovatriptan revenues to raise cash and cancel debt has strengthened the balance sheet and provided the financial platform to invest in our product pipeline and discovery programmes. I am also very pleased to announce today that we have successfully completed our Phase IIa ischaemic stroke study with V10153, and have identified a safe dose to take through to efficacy studies next year in this very underserved market. ”

MRC Showcase – Vaccines and Immunotherapies

MRC-funded researchers and industry showcase attendees have the opportunity to apply for collaborative grants from the Pilot Industry Award Scheme, for which a budget of £3 million has been committed for 2007/08.

The aim of MRC showcases is to encourage collaboration between MRC scientists and industry.

An early bird discount applies if you register before 31/08/08 – ONLY £500 (Normally £750). Simply visit http://www.mrcshowcases.org/industry-registration.html to register and the discount will automatically be applied.

Full details and the outline programme can be found on the Showcases website at www.mrcshowcases.org

For more information on how your company can benefit please read the PDF brochure http://www.mrcshowcases.org/MRC_vaccines_immunotherapies_showcase_industry_leaflet.pdf or contact Ranmali Nawaratne on 020 7291 5304 or rnawaratne@tech.mrc.ac.uk